Analysts have revised their price target for Bonesupport Holding from SEK 419.75 to SEK 401.80. This change reflects adjustments to growth and profitability assumptions.
What's in the News
- Bonesupport announced positive clinical study results indicating significantly improved patient-reported outcomes for CERAMENT G in single-stage revision surgery for periprosthetic joint infection (PJI) of the hip. (Key Developments)
- The study, conducted at Charite Universitatsmedizin Berlin with twenty patients, showed no re-infections during a 24-month follow-up. (Key Developments)
- Patient-reported scores such as the Harris Hip Score, EQ-5D-5L, and Pain Visual Analogue Scale demonstrated notable improvements following the single-stage procedure. (Key Developments)
- These results were presented at the European Bone and Joint Infection Society annual meeting, with publication of the study (CeraHip) anticipated in the autumn. (Key Developments)
- The single-stage procedure using CERAMENT G addresses a high re-infection rate associated with the current two-stage standard for hip revision surgery. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has decreased from SEK 419.75 to SEK 401.80.
- Discount Rate has risen slightly from 4.92% to 4.96%.
- Revenue Growth forecasts have increased from 35.2% to 39.8%.
- Net Profit Margin estimates have fallen from 32.1% to 30.3%.
- Future P/E (Price/Earnings) multiple forecast has decreased from 37.93x to 33.06x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.